| 1 |
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Caroline Robert et al. · New England Journal of Medicine
|
5 Jun 2011 |
4,523 |
| 2 |
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Brian I. Rini et al. · New England Journal of Medicine
Open access |
16 Feb 2019 |
3,488 |
| 3 |
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
Tony S.K. Mok et al. · The Lancet
Open access258 authors |
4 Apr 2019 |
3,392 |
| 4 |
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
Luis G Paz-Ares et al. · The Lancet
246 authors |
4 Oct 2019 |
2,310 |
| 5 |
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
Richard S. Finn, John P. Crown, István Láng et al. · The Lancet Oncology
|
15 Dec 2014 |
1,934 |
| 6 |
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
Massimo Cristofanilli, Nicholas C. Turner, Igor Bondarenko et al. · The Lancet Oncology
Open access |
2 Mar 2016 |
1,870 |
| 7 |
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
Georgina Venetia Long et al. · The Lancet
|
31 May 2015 |
1,419 |
| 8 |
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
Caroline Robert et al. · New England Journal of Medicine
Open access |
4 Jun 2019 |
1,412 |
| 9 |
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
Nicholas C. Turner, Dennis J. Slamon, Jungsil Ro et al. · New England Journal of Medicine
Open access |
20 Oct 2018 |
1,321 |
| 10 |
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial
Martin Reck, Rolf Kaiser, Anders Mellemgaard et al. · The Lancet Oncology
Open access |
8 Jan 2014 |
962 |
| 11 |
Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double‐blind, placebo‐controlled trial
Sonia S. Hassan et al. · Ultrasound in Obstetrics and Gynecology
Open access |
6 Apr 2011 |
940 |
| 12 |
Different approaches for interpretation and reporting of immunohistochemistry analysis results in the bone tissue – a review
Nickolay Fedchenko, Janin Reifenrath · Diagnostic Pathology
Open access |
28 Nov 2014 |
828 |
| 13 |
Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial
Ahmet Sezer et al. · The Lancet
|
Feb 2021 |
814 |
| 14 |
Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study
Carsten Bokemeyer, Igor Bondarenko, J.T. Hartmann et al. · Annals of Oncology
Open access |
12 Jan 2011 |
786 |
| 15 |
Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial
Thomas Powles, Elizabeth R. Plimack, Denis Soulières et al. · The Lancet Oncology
|
23 Oct 2020 |
763 |
| 16 |
Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
Jonathan Wade Goldman et al. · The Lancet Oncology
Open access253 authors |
4 Dec 2020 |
707 |
| 17 |
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study
Georgina Venetia Long et al. · Annals of Oncology
Open access |
3 May 2017 |
668 |
| 18 |
Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial
John F.R. Robertson, Igor M Bondarenko, Ekaterina Trishkina et al. · The Lancet
Open access |
28 Nov 2016 |
606 |
| 19 |
Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study
Steven J O'Day, Michele Maio, Vanna Chiarion‐Sileni et al. · Annals of Oncology
Open access |
11 Feb 2010 |
514 |
| 20 |
RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections
J. Motsch, Cláudia Murta de Oliveira, Viktor P. Stus et al. · Clinical Infectious Diseases
Open access |
25 Jun 2019 |
426 |
| 21 |
FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma
Uğur Şahin, Ö. Türeci, Georgy Moiseevich Manikhas et al. · Annals of Oncology
Open access |
21 Feb 2021 |
380 |
| 22 |
Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN
Luis G Paz-Ares et al. · ESMO Open
Open access |
10 Mar 2022 |
349 |
| 23 |
Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial
Daniel V.T. Catenacci et al. · The Lancet Oncology
Open access |
25 Sep 2017 |
349 |
| 24 |
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non–Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study
Gilberto de Castro, Iveta Kudaba, Yi-Long Lung Cancer Wu et al. · Journal of Clinical Oncology
Open access |
28 Oct 2022 |
343 |
| 25 |
Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial
Veronique C Dieras et al. · The Lancet Oncology
Open access |
27 Aug 2020 |
322 |
| 26 |
Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer
Ahmad Hussein Awada, Rámón Colomer, Kenichi Inoue et al. · JAMA Oncology
Open access |
14 Apr 2016 |
319 |
| 27 |
Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection
Keith S. Kaye et al. · JAMA
Open access |
27 Feb 2018 |
314 |
| 28 |
A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy
Matti Aapro, H. S. Rugo, Antônio Rossi et al. · Annals of Oncology
Open access |
7 Mar 2014 |
251 |
| 29 |
Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study
Paul Joseph Hesketh, Antônio Rossi, Giada Rizzi et al. · Annals of Oncology
Open access |
9 Mar 2014 |
228 |
| 30 |
Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
Michele Maio et al. · The Lancet Oncology
Open access141 authors |
21 Feb 2018 |
219 |
| 31 |
Efficacy and Safety Analysis of Nelipepimut-S Vaccine to Prevent Breast Cancer Recurrence: A Randomized, Multicenter, Phase III Clinical Trial
Elizabeth Ann Mittendorf, Biao Lu, Michelle Melisko et al. · Clinical Cancer Research
|
29 Apr 2019 |
216 |
| 32 |
Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2− ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study
Massimo Cristofanilli, Hope S. Rugo, Seock‐Ah Im et al. · Clinical Cancer Research
Open access |
12 May 2022 |
210 |
| 33 |
MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial
Brigitte Dréno et al. · The Lancet Oncology
|
13 Jun 2018 |
206 |
| 34 |
Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study
Heather S. Han et al. · Annals of Oncology
Open access |
28 Sep 2017 |
204 |
| 35 |
The probiotic Escherichia coli strain Nissle 1917 (EcN) stops acute diarrhoea in infants and toddlers
Jobst Henker, Martin Walter Laass, Boris M. Blokhin et al. · European Journal of Pediatrics
Open access |
7 Feb 2007 |
195 |
| 36 |
Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study
Lloyd Mayer, William J. Sandborn, Yu.M. Stepanov et al. · Gut
Open access |
5 Mar 2013 |
192 |
| 37 |
Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18
Richard S. Finn, John P. Crown, Johannes Ettl et al. · Breast Cancer Research
Open access |
27 Jun 2016 |
187 |
| 38 |
Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18)
Richard S. Finn, Katalin Boér, Igor Bondarenko et al. · Breast Cancer Research and Treatment
Open access |
18 Jul 2020 |
174 |
| 39 |
Randomized, Multicenter, Phase II Study of CO-101 Versus Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma: Including a Prospective Evaluation of the Role of hENT1 in Gemcitabine or CO-101 Sensitivity
Elizabeth A. Poplin et al. · Journal of Clinical Oncology
Open access |
13 Nov 2013 |
161 |
| 40 |
From transformation to chronification of migraine: pathophysiological and clinical aspects
Marta Torres‐Ferrús et al. · The Journal of Headache and Pain
Open access |
29 Apr 2020 |
155 |
| 41 |
Fosfomycin for Injection (ZTI-01) Versus Piperacillin-tazobactam for the Treatment of Complicated Urinary Tract Infection Including Acute Pyelonephritis: ZEUS, A Phase 2/3 Randomized Trial
Keith S. Kaye, Louis B. Rice, Aaron L. Dane et al. · Clinical Infectious Diseases
Open access |
28 Feb 2019 |
151 |
| 42 |
Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)–Positive Metastatic Breast Cancer
Hope S. Rugo et al. · JAMA
Open access |
5 Dec 2016 |
147 |
| 43 |
Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study
Elizabeth R. Plimack et al. · European Urology
|
24 Jul 2023 |
146 |
| 44 |
Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial
Rebecca Kristeleit et al. · The Lancet Oncology
|
14 Mar 2022 |
145 |
| 45 |
A randomized controlled phase II trial of a novel composition of paclitaxel embedded into neutral and cationic lipids targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC)
Ahmad Hussein Awada, Igor Bondarenko, Jean Bonneterre et al. · Annals of Oncology
Open access |
25 Mar 2014 |
141 |
| 46 |
Ischemia-Modified Albumin: Origins and Clinical Implications
А. И. Шевцова, Iu. A. Gordiienko, Viktoriia Tkachenko et al. · Disease Markers
Open access |
19 Jul 2021 |
136 |
| 47 |
Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation
David W. Miles, David Cameron, Igor Bondarenko et al. · European Journal of Cancer
|
4 Nov 2016 |
126 |
| 48 |
Emergency care of patients receiving non-vitamin K antagonist oral anticoagulants
John W. Eikelboom, SIBYLLE A. KOZEK‐LANGENECKER, A. Exadaktylos et al. · British Journal of Anaesthesia
Open access |
19 Dec 2017 |
124 |
| 49 |
Randomized Phase III Trial Comparing Single-Agent Paclitaxel Poliglumex (CT-2103, PPX) with Single-Agent Gemcitabine or Vinorelbine for the Treatment of PS 2 Patients with Chemotherapy-Naïve Advanced Non-small Cell Lung Cancer
Mary E.R. O'Brien, Mark A. Socinski, Alexander Y. Popovich et al. · Journal of Thoracic Oncology
Open access |
Jul 2008 |
124 |
| 50 |
Altered expression of NCAM in hippocampus and cortex may underlie memory and learning deficits in rats with streptozotocin-induced diabetes mellitus
Gıyasettin Baydaş, Viktor S Nedzvetskii, Peter A. Nerush et al. · Life Sciences
|
22 Jul 2003 |
113 |